Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiovascular effects of apelin infusion in healthy male subjects
NL-OMON39109Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2012
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Randomised, open-label trial of Apelin (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Hemodynamic assessments, Cardiac index and 11 more. Started Jul 2012; status: active, not recruiting.
02
Drugs
Apelin
Beyond the preview
Go deeper on NL-OMON39109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39109.